The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus

Clinical Nutrition

Volumn 35, Issue 5, 2016, Pages 1091-1095

  Derosa, Giuseppe ^a,b   D'Angelo, Angela ^a   Maffioli, Pamela ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Berberis aristata; Insulin consumption; Silybum marianum; Type 1 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; BERBEROL; CREATINE KINASE; CREATININE; INSULIN; PLACEBO; UNCLASSIFIED DRUG; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; PLANT MEDICINAL PRODUCT; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF COVARIANCE; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BERBERIS ARISTATA; BODY MASS; BODY WEIGHT; CAUCASIAN; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; GOOD CLINICAL PRACTICE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SILYBUM MARIANUM; SYSTOLIC BLOOD PRESSURE; BERBERIS; BLOOD; CHEMISTRY; DOSE RESPONSE; FOLLOW UP; GLUCOSE BLOOD LEVEL; METABOLISM; PHYTOTHERAPY; YOUNG ADULT;

ADULT; BERBERIS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HUMANS; INSULIN; MALE; MILK THISTLE; PHYTOTHERAPY; PLANT PREPARATIONS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84941712475     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2015.08.004     Document Type: Article

References (19)

1. [1] American Diabetes Association, Standards of medical care in diabetes-2014. Diabetes Care 37:Suppl. 1 (2014), S14–S80.
2. [2] United Kingdom Prospective Diabetes Study Group, Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 353 (1998), 837–853 Proposed International Guidelines for Biomedical Research Involving Human Subjects. The Council for International Organisation of Medical Sciences. Geneva, 1982.
3. [3] Derosa, G., Maffioli, P., Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice. Expert Rev Endocr Metab, 2014, 10.1586/17446651.2015.995630.
4. [4] Derosa, G., Maffioli, P., Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. Curr Top Med Chem 14:2 (2014), 200–206.
5. [5] Derosa, G., Maffioli, P., Cicero, A.F., Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 12:8 (2012), 1113–1124.
6. [6] Di Pierro, F., Villanova, N., Agostini, F., Marzocchi, R., Soverini, V., Marchesini, G., Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes 5 (2012), 213–217.
7. [7] Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., D'Angelo, A., Fogari, E., et al. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther 13:11 (2013), 1495–1506.
8. [8] Zhou, J., Zhou, S., Tang, J., Zhang, K., Guang, L., Huang, Y., et al. Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur J Pharmacol 606 (2009), 262–268.
9. [9] Proposed international guidelines for biomedical research involving human subjects, 1982, The Council for International Organisation of Medical Sciences, Geneva.
10. [10] 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 17 (1999), 151–183.
11. [11] NCEP, Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:25 (2002), 3143–4216.
12. [12] Derosa, G., D'Angelo, A., Bonaventura, A., Bianchi, L., Romano, D., Maffioli, P., Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin Biol Ther 13:4 (2013), 475–482.
13. [13] Winer, B.J., Statistical principles in experimental design. 2nd ed., 1971, McGraw-Hill, New York (USA).
14. [14] Weir, G., Bonner-Weir, S., Leahy, J., Islet mass and function in diabetes and transplantation. Diabetes 39 (1990), 401–405.
15. [15] Soto, C., Raya, L., Pérez, J., González, I., Pérez, S., Silymarin induces expression of pancreatic Nkx6.1 transcription factor and β-cells neogenesis in a pancreatectomy model. Molecules 19:4 (2014), 4654–4668.
16. [16] Di Pierro, F., Putignano, P., Villanova, N., Montesi, L., Moscatiello, S., Marchesini, G., Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol 5 (2013), 167–174.
17. [17] Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., D'Angelo, A., Fogari, E., et al. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J Biol Regul Homeost Agents 27:3 (2013), 717–728.
18. [18] Skottová, N., Vecera, R., Urbánek, K., Vána, P., Walterová, D., Cvak, L., Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharmacol Res 47:1 (2003), 17–26.
19. [19] Sobolová, L., Skottová, N., Vecera, R., Urbánek, K., Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats. Pharmacol Res 53:2 (2006), 104–112.